Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

Can you expand on the off-label use of IL-17, IL-12, and IL-23 inhibitors for HS?

Hidradenitis Suppurativa

You. So HS is a very hard disease to treat. While we do have an FDA approved biologic for HS, not all patients respond to Humira, the FDA approved biologic for HS. I have used sort of other biologics off label in my practice for HS. Certainly aisle 17 blockage does seem to be promising, and cosentics does have a clinical trial looking at its efficacy in HS, and they are awaiting on FDA approval, which could take some time. So clearly, we do know that IL 17 blockage can play a role in HS. So that's one thing. As far as IL 1223 blockage goes, they did do a sort of open label clinical trial with a eusticinamab for HS, and it did show some trend towards improvement. But then again, it was a small study with just 17 patients, so it's kind of hard to sort of draw inferences on a wider scale. But certainly, if you do have a patient that hasn't responded to an anti tnF, considering biologics that have other mechanisms of action seems worthwhile. Lastly, as far as IL 23 blockage goes, the selkimab is being investigated in a clinical trial with HS patients. So let's see what pans out of that study. But it's too early to tell.

Can you expand on the off-label use of IL-17, IL-12, and IL-23 inhibitors for HS?

Related CME